New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
09:31 EDTABBVAbbVie sees adjusted Q1 EPS 67c-69c, consensus 67c
Comment made on the Q4 earnings conference call.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent ABBV news | >>
May 27, 2015
06:25 EDTABBVAbbVie reinstated with an Overweight at JPMorgan
JPMorgan reinstated its Overweight rating on shares of AbbVie and raised its price target for shares to $75 from $73. The firm views the valuation as "inexpensive" and views the Pharmacyclics acquisition as adding a "solid" growth platform.
May 26, 2015
19:16 EDTABBVEnanta says may receive $30M milestone payment from AbbVie upon Japan approval
In reference to the release of GIFT-1 study data, Enanta (ENTA) stated that upon commercialization regulatory approval [sic] in Japan of AbbVie's (ABBV) treatment regimen related to GIFT-1, Enanta will be entitled to a $30M milestone payment from AbbVie. In addition, Enanta will be eligible to receive annually tiered royalties, ranging from the low double digits up to 20%, on AbbVies aggregate net sales of all paritaprevir-containing regimens, including 45% of AbbVies worldwide net sales of any two direct-acting antivirals regimen.
19:07 EDTABBVAbbVie presents phase 3 GIFT-I data, says achieved primary endpoint
Subscribe for More Information
10:46 EDTABBVAnthem sued for denying coverage for Gilead's Harvoni, WSJ says
Subscribe for More Information
08:32 EDTABBVAbbVie completes acquisition of Pharmacyclics
Subscribe for More Information
08:03 EDTABBVInfinity Pharmaceuticals reports preclinical data for duvelisib
Subscribe for More Information
May 22, 2015
08:00 EDTABBVAbbVie announces expiration of HSR waiting period for Pharmacyclics acquisition
AbbVie (ABBV) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of Pharmacyclics (PCYC) has expired today. The expiration satisfies the exchange offer condition with respect to the approvals and clearances required under antitrust laws. Assuming that the other customary exchange offer conditions are satisfied, including a minimum tender of at least a majority of outstanding Pharmacyclics shares, it is expected that the exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics will expire today at 5:00 p.m., New York City time, without any further extension.
May 21, 2015
08:04 EDTABBVAbbVie announces offer consideration for acquisition of Pharmacyclics
AbbVie (ABBV) announced the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics (PCYC) for a mix of cash and AbbVie common stock, as described in the Registration Statement on Form S-4 filed with the SEC by AbbVie on March 23, 2015, as amended. The mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie common stock.
07:58 EDTABBVDeutsche sees AbbVie shares getting to $80 over summer
Deutsche Bank sees pipeline readouts over the summer pushing shares of AbbVie to $80. The firm keeps a Buy rating on the stock with an $80 price target after meting with management.
07:37 EDTABBVPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
09:07 EDTABBVJohnson & Johnson says exploring eight new indications for Imbruvica
Imbruvica is jointly developed and commercialized by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ) subsidiary Janssen Biotech. AbbVie (ABBV) is in the process of acquiring Pharmacyclics.
07:21 EDTABBVUBS to hold a conference
Subscribe for More Information
May 19, 2015
08:57 EDTABBVLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 15, 2015
16:46 EDTABBVAbbVie extends exchange offer to acquire Pharmacyclics
AbbVie (ABBV) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics (PCYC) to 5 p.m., New York City time, on May 22. The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on May 15, a total of approximately 42,822,941 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer. All other terms and conditions of the exchange offer remain unchanged.
10:29 EDTABBVAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:45 EDTABBVAbbVie reports FDA orphan designation for Humira in treatment of HS
Subscribe for More Information
May 14, 2015
13:12 EDTABBVAbbVie granted orphan status for Humira
Subscribe for More Information
10:41 EDTABBVAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:09 EDTABBVBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
May 13, 2015
13:12 EDTABBVSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
1 | 2 | all recent ABBV news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use